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Figure 1. Pain and Symptoms Pre-, During, and Post-Collection in Older
Related Donors
Abstracts / Biol Blood Marrow Transplant 20 (2014) S27eS44S42baseline (only 3 donors had grade 3) were more likely to
experience grade 2-4 pain (62 vs. 28%; p¼0.001) and grade 2-
4 symptoms (35 vs. 14%; p¼0.01) on day 5 of G-CSF. Female
donors showed lower rates of return to baseline symptom
levels at one month (72 vs. 85%, female vs. male; p¼0.028).
Race and ages 61-65, 66-70, and 71+ had no effect.
Conclusions: Related donors over age 60 have high baseline
rates of pain and other symptoms. Their rate of any grade
pain is lower but grade 3-4 pain is higher on the day of
collection and recovery at one month is slower than noted in
past studies of younger unrelated donors. Donors with
baseline pain are at risk of experiencing higher levels of pain
and symptoms during the collection process, and women
recovermore slowly thanmen. Additional analyses including
baseline organ-speciﬁc comorbidities and multivariable
analysis of risk will be presented with these data.
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Background: Female donors for male recipients worsens
outcome of allogeneic haematopoietic stem cell trans-
plantation (HSCT). We wanted to ﬁnd out whether a maleHLA-matched unrelated donor (MUD, 8/8, n¼2,014)might be
an alternative to a female HLA-identical sibling donor
(n¼2,656) for males with acute leukaemia.
Methods: A retrospective analysis from the Acute Leukemia
Working Party of the European Group for Blood and Marrow
Transplantation.
Results: The relative risk (RR) of acute GVHD of grades IIeIV
was increased in the MUD group with acute myeloid
leukaemia (AML) (RR 1.47, p<0.001) and acute lymphoblastic
leukaemia (ALL) (RR 1.76, p<0.001). There was no difference
in incidence of chronic GVHD and non-relapse mortality
between the two groups. Probability of relapse was lower in
the MUD group than in the sibling group in ALL patients (HR
0.75, p¼0.04) but not in AML patients (HR 0.89, p¼0.17).
Survival was not different between the groups. Leukaemia-
free survival (LFS) was also similar in the sibling and MUD
groups in patients with AML (HR 1.01, p¼0.81) or ALL (HR
0.93, p¼0.45). Factors signiﬁcantly associated with reduced
LFS included active disease, poor cytogenetics, age, year of
HSCT, reduced-intensity conditioning, and the use of anti-
thymocyte globulin.
Conclusion: Male patients who received grafts from male
MUDs had an increased incidence of acute GVHD and the
same LFS as when using HLA-identical female donors.32
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We have previously reported a lower than expected inci-
dence of acute GVHD in recipients of sibling donor allogeneic
HSC transplants mobilized with GM-CSF alone (Devine et al.
BMT 2005). However, the use of GM-CSF as a single agent for
stem cell mobilization has been limited by a high (w30%)
incidence of failure to mobilize and collect adequate stem
cell numbers in a single apheresis procedure. Based on
observed synergy between GM-CSF and plerixafor for HSC
mobilization in mice, we hypothesized that this combination
in humansmight overcome the low stem cell yields observed
with either agent alone and result in a PBSC product enriched
in Tregs and MDSCs that could reduce GvHD after transplant.
The efﬁcacy of GM-CSF (initially given 10 mcg/kg SC daily x 5
e 6 days but reduced to 5mcg/kg daily secondary to toxicity),
and plerixafor (320 mcg/kg IV daily starting on day 5) was
tested in a phase II trial.
The primary objective of this trial was reduction in the day 1
mobilization failure rate from 33% to <10%. We planned to
enroll 17 donor recipient pairs. Donors failing to reach 20L
apheresis volume were replaced. To date 22 donors (4 at
10mcg/kg GM-CSF and 18 at 5mcg/kg GM-CSF) have been
mobilized and 19 recipients transplanted. Initial mobilization
with GM-CSF 10mcg/kg was complicated by catheter and IV
tubing-associated thrombosis at the time of apheresis in 4/4
donors. Because of this, GM-CSF dose was reduced to 5 mcg/
kg SC daily x 5e6 days. Since this dose reduction, access
complications have occurred in 3/18 donors that precluded a
full 20 L apheresis. There has been no grade 3e4 adverse
events related to mobilization.
